Keverprazan Hydrochloride: First Approval

Keverprazan hydrochloride (sic) is a potassium ion competitive acid blocker that is being developed by Jiangsu Carephar Pharmaceuticals for the treatment of acid-related disease. Keverprazan hydrochloride was recently approved in China for the treatment of adults with reflux oesophagitis or duodenal ulcer. This article summarizes the milestones in the development of keverprazan hydrochloride leading to this first approval for reflux oesophagitis and duodenal ulcer.

Automated summary

Keverprazan hydrochloride, developed by Jiangsu Carephar Pharmaceuticals, is a potassium ion competitive acid blocker used for the treatment of acid-related diseases. It has recently been approved in China for the treatment of reflux esophagitis and duodenal ulcer in adults. This article summarizes the development milestones of keverprazan hydrochloride leading to its first approval for reflux esophagitis and duodenal ulcer treatment.